Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy

Amit G. Singal(Southwestern Medical Center), Fasiha Kanwal(Michael E. DeBakey VA Medical Center), Josep M. Llovet(Institució Catalana de Recerca i Estudis Avançats)

Nature Reviews Clinical Oncology

October 26, 2023

10.1038/s41571-023-00825-3

Cited by 780

Abstract

Related Papers

Sorafenib in Advanced Hepatocellular Carcinoma

Josep M. Llovet, Sergio Ricci, Vincenzo Mazzaferro et al.|New England Journal of Medicine|2008|12.9k

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Ann‐Lii Cheng, Yoon‐Koo Kang, Zhendong Chen et al.|The Lancet Oncology|2008|5.8k

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

Josep M. Llovet, Jordi Bruix|Hepatology|2003|3k

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

Andrew X. Zhu, Joon Oh Park, Baek‐Yeol Ryoo et al.|The Lancet Oncology|2015|845

Downstaging of hepatocellular cancer before liver transplant: Long‐term outcome compared to tumors within Milan criteria

Francis Y. Yao, Neil Mehta, Jennifer A. Flemming et al.|Hepatology|2015|478